Greenwich Lifesciences Inc (GLSI)

$8.62

Live

Insights on Greenwich Lifesciences Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 66.6% return, outperforming this stock by 80.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 155.7% return, outperforming this stock by 54.8%

Performance

  • $8.55
    $8.75
    $8.62
    downward going graph

    0.81%

    Downside

    Day's Volatility :2.29%

    Upside

    1.49%

    downward going graph
  • $7.81
    $21.50
    $8.62
    downward going graph

    9.4%

    Downside

    52 Weeks Volatility :63.67%

    Upside

    59.91%

    downward going graph

Returns

PeriodGreenwich Lifesciences IncSector (Health Care)Index (Russel 2000)
3 Months
-7.71%
-3.2%
0.0%
6 Months
-32.92%
-2.7%
0.0%
1 Year
-13.71%
0.8%
-0.4%
3 Years
101.4%
22.3%
14.9%

Highlights

Market Capitalization
118.6M
Book Value
$0.83
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.68
Wall Street Target Price
38.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-41.15%
Return On Equity TTM
-64.18%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-9.3M
Diluted Eps TTM
-0.68
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.89
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
-0.23
EPS Estimate Next Quarter
-0.22

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Greenwich Lifesciences Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 340.84%

Current $8.62
Target $38.00

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Greenwich Lifesciences Inc
Greenwich Lifesciences Inc
-4.86%
-32.92%
-13.71%
101.4%
72.4%
Moderna, Inc.
Moderna, Inc.
-5.74%
-34.14%
-17.98%
43.27%
454.19%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.77%
-1.68%
9.3%
33.59%
106.18%
Novo Nordisk A/s
Novo Nordisk A/s
-7.65%
10.71%
66.6%
150.37%
305.83%
Seagen, Inc.
Seagen, Inc.
2.57%
3.72%
52.7%
4.95%
167.21%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.89%
9.77%
14.81%
28.32%
82.99%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Greenwich Lifesciences Inc
Greenwich Lifesciences Inc
NA
NA
NA
-0.89
-0.64
-0.41
0.0
0.83
Moderna, Inc.
Moderna, Inc.
34.44
34.44
0.0
-3.45
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
21.94
21.94
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
43.71
43.71
2.03
1.66
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.05
27.05
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Greenwich Lifesciences Inc
Greenwich Lifesciences Inc
Buy
$118.6M
72.4%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.3B
454.19%
34.44
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$88.8B
106.18%
21.94
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$411.7B
305.83%
43.71
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$39.7B
167.21%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$89.1B
82.99%
27.05
35.4%

Institutional Holdings

  • Vanguard Group Inc

    2.20%
  • Renaissance Technologies Corp

    0.62%
  • Ameriprise Financial Inc

    0.53%
  • BlackRock Inc

    0.45%
  • Geode Capital Management, LLC

    0.31%
  • Millennium Management LLC

    0.28%

Corporate Announcements

  • Greenwich Lifesciences Inc Earnings

    Greenwich Lifesciences Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

Organization
Greenwich Lifesciences Inc
Employees
3
CEO
Mr. Snehal S. Patel
Industry
Health Technology

FAQs